More than 1 million prescriptions for the COVID-19 antiviral pills Lagevrio and Paxlovid were dispensed between late December 2021 and May 2022, but dispensing rates were lowest in the most socially and economically disadvantaged communities, according to a study released today by the Centers for Disease Control and Prevention. In a separate study of electronic health records from Kaiser Permanente Southern California over the period, fewer than 1% of patients aged 12 and older who received Paxlovid to treat mild-to-moderate COVID-19 had a COVID-19-related hospitalization or emergency department visit in the next five to 15 days. CDC said the studies “highlight the importance of ensuring access to oral antiviral medicine in treating COVID-19, a key strategy in preventing hospitalization and death.”

Related News Articles

Headline
In the first of two new blogs in the Institute for Diversity and Health Equity’s monthly series highlighting Black women health care leaders, Dana Weston…
Headline
The Food and Drug Administration today released final guidance for transitioning medical device enforcement policies and emergency use authorizations…
Blog
You don’t find these roles. These roles find you.   As an African American woman that has had a fulfilling career, my life has been a series of…
Blog
“Be who you needed when you were younger.” When I first heard these eight words more than a decade ago, they stopped me in my tracks.  Who had I needed as…
Headline
Health delivery organizations are invited to apply through May 17 for the 2024 Foster G. McGaw Prize, which honors organizations that demonstrate a strategic…
Headline
Health and Human Services Secretary Xavier Becerra this week amended the February 2020 COVID-19 emergency use authorization declaration so that the Food…